Combination chemotherapy with vincristine and methotrexate for advanced refractory breast cancer
- 1 July 1979
Abstract
Eighteen patients with advanced breast cancer refractory to combination chemotherapy with 5-FU, Adriamycin, Cytoxan (FAC) were treated with methotrexate 30 to 40 mg/m2 iv and vincristine 1.5 mg/m2 iv at weekly intervals. Of 17 evaluable patients, 4 (23%) achieved a partial remission with a median duration of remission of 6 months and a median survival of 10 months. In another seven of seventeen patients (41%) the disease remained stable. Toxicity was minimal.This publication has 7 references indexed in Scilit:
- Combination chemoimmunotherapy of metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, and BCGCancer, 1979
- A randomized comparative trial of adriamycin versus methotrexate in combination drug therapyCancer, 1978
- HEXAMETHYLMELAMINE, VINCRISTINE, AND METHOTREXATE CHEMOTHERAPY IN ADVANCED NEOPLASMS1977
- Chemoimmunotherapy of advanced breast cancer: prolongation of remission and survival with BCG.BMJ, 1976
- Combination chemotherapy with adriamycin and cyclophosphamide for advanced breast cancerCancer, 1975
- Phase II study of hexamethylmelamine (NSC 13875)Cancer, 1969
- Methotrexate for advanced cancer of the breastCancer, 1968